Skip to main content
SpringerLink
Log in

Anticoagulation for acute coronary syndromes and percutaneous coronary intervention in patients with heparin-induced thrombocytopenia

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Heparin-induced thrombocytopenia (HIT) is not uncommon in clinical practice, and may go unrecognized in a substantial number of patients. The pathophysiology of HIT has only recently been better understood. Patients with HIT may require anticoagulation for thrombotic complications that result in severe morbidity and mortality. These patients may also require anticoagulation for acute coronary syndromes (ACS), or during percutaneous coronary interventions (PCIs). The direct thrombin inhibitors are currently the anticoagulant of choice in HIT patients with ACS or those undergoing PCI, based on data from several large clinical trials in ACS and PCI populations, and data from smaller experiences, specifically in patients with HIT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Fahey VA: Heparin-induced thrombocytopenia. J Vasc Nurs 1995, 13:112–116.

    Article  PubMed  CAS  Google Scholar 

  2. Brieger DB, Mak KH, Kottke-Marchant K, et al.: Heparin-induced thrombocytopenia. J Am Coll Cardiol 1998, 31:1449–1459. Excellent review article of HIT. Good discussion of pathophysiology, clinical presentation, and treatment options.

    Article  PubMed  CAS  Google Scholar 

  3. Aster RH: Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 1995, 332:1374–1376.

    Article  PubMed  CAS  Google Scholar 

  4. Eikelboom JW, Anand SS, Mehta SR, et al.: Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome with ST elevation: Organization to assess strategies for ischemic syndromes (OASIS-2) Study. Circulation 2001, 103:643–650.

    PubMed  CAS  Google Scholar 

  5. McClure MW, Berkowitz SD, Sparapani R, et al.: Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome: the PURSUIT trial experience. Circulation 1999, 99:2892–2900.

    PubMed  CAS  Google Scholar 

  6. Berkowitz SD, Sparapani RA, Califf RM, et al.: Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. J Am Coll Cardiol 1998, 32:387–392.

    Article  Google Scholar 

  7. Kaplan KL, Broekman MJ, Chernoff A, et al.: Platelet alpha granule proteins: studies on release and subcellular localization. Blood 1979, 53:604–608.

    PubMed  CAS  Google Scholar 

  8. Amiral J, Bridey F, Dreyfus M, et al.: Platelet factor 4 complexed to heparin is the target for antibodies generated in heparininduced thrombocytopenia. Thromb Haemost 1992, 68:95–96.

    PubMed  CAS  Google Scholar 

  9. Amiral J, Wolf M, Fisher AM, et al.: Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 1996, 92:954–959.

    Article  PubMed  CAS  Google Scholar 

  10. Amiral J, Marfaing-Koka A, Wolf M, et al.: Presence of autoantibodies to interleukin-8 or neutrophil activating peptide-2 in patients with heparin associated thrombocytopenia. Blood 1996, 88:410–416.

    PubMed  CAS  Google Scholar 

  11. Chong BH, Fawaz I, Chesterman CN, et al.: Heparin induced thrombocytopenia: mechanism of interaction of the heparin dependent antibody with the platelets. Br J Haematol 1989, 73:235–240.

    PubMed  CAS  Google Scholar 

  12. Rubinstein E, Boucheix C, Worthington RE, et al.: Anti-platelet antibody interactions with the Fcy receptor. Semin Thromb Hemost 1995, 21:10–22.

    PubMed  CAS  Google Scholar 

  13. Burgess JK, Lindeman R, Chesterman CN, et al.: Single amino acid mutation of Fcy receptor is associated with the development of heparin induced thrombocytopenia. Br J Haematol 1995, 91:761–766.

    PubMed  CAS  Google Scholar 

  14. Visentin GP, Ford SE, Scott JP, et al.: Antibodies from patients with heparin induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994, 93:81–88.

    Article  PubMed  CAS  Google Scholar 

  15. Wallis DE, Workman DL, Lewis BE, et al.: Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999, 106:629–635.

    Article  PubMed  CAS  Google Scholar 

  16. Antman EM, Cohen M, Radley D, et al.: Assessment of the treatment effect of enoxaparin for unstable angina/non-Q wave myocardial infarction: TIMI-11B-ESSENCE metaanalysis. Circulation 1999, 100:1602–1608.

    PubMed  CAS  Google Scholar 

  17. Ramakrishna R, Manoharan A, Kwan YL, et al.: Heparin induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Organon). Br J Haematol 1992, 91:736–738.

    Google Scholar 

  18. Magnani HN: Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993, 70:554–561.

    PubMed  CAS  Google Scholar 

  19. Tardy-Poncet B, Tardy B, Reynaud J, et al.: Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia. Chest 1999, 115:1616–1620.

    Article  PubMed  CAS  Google Scholar 

  20. Hale LP, Smith K, Braden GA, et al.: Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia. Cathet Cardiovasc Diagn 1998, 45:318–322.

    Article  PubMed  CAS  Google Scholar 

  21. Cantor WJ, Leblanc K, Garvey B, et al.: Combined use of Orgaran and Reopro during coronary angioplasty in patients unable to receive heparin. Cathet Cardiovasc Intervent 1999, 46:352–355.

    Article  CAS  Google Scholar 

  22. Demers C, Ginsberg JS, Brill-Edwards P, et al.: Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood 1991, 78:2194–2197.

    PubMed  CAS  Google Scholar 

  23. Cole CW, Fournier LM, Bormanis J: Heparin associated thrombocytopenia and thrombosis: optimum therapy with ancrod. Can J Surg 1990, 33:207–210.

    PubMed  CAS  Google Scholar 

  24. Haas S, Walenga JM, Jeske WP, et al.: Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications. Semin Thromb Hemost 1999, 25(Suppl 1):67–75.

    PubMed  CAS  Google Scholar 

  25. Polgar J, Eichler P, Greinacher A, et al.: Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from heparininduced thrombocytopenia patients. Blood 1998, 91:549–554.

    PubMed  CAS  Google Scholar 

  26. The ESPRIT Investigators: Novel dosing regimen of eptifibatide in planned coronary stent implantation: a randomised placebo controlled trial. Lancet 2000, 356:2037–2044.

    Article  Google Scholar 

  27. The EPISTENT Investigators: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998, 352:87–92.

    Article  Google Scholar 

  28. Walenga JM, Jeske WP, Wallis DE, et al.: Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT. Semin Thromb Hemost 1999, 25(suppl 1):77–81.

    PubMed  CAS  Google Scholar 

  29. Jeske WP, Walenga JM, Szatkowski E, et al.: Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets. Thromb Res 1997, 88:271–281.

    Article  PubMed  CAS  Google Scholar 

  30. Jeske WP, Mousa SA, Yang LG: Short-acting glycoprotein IIb/ IIIa inhibitors may be safer for the management of patients with active heparin induced thrombocytopenic syndrome. Blood 1998, 92:181A.

    Google Scholar 

  31. Hursting MJ, Alford KL, Becker JP, et al.: Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin Thromb Hemost 1997, 23:503–516.

    PubMed  CAS  Google Scholar 

  32. Lewis BE, Walenga JM, Wallis DE: Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost 1997, 23:197–202.

    Article  PubMed  CAS  Google Scholar 

  33. Fenton JW II, Villanueva GB, Ofosu FA, et al.: Thrombin inhibition by hirudin: how hirudin inhibits thrombin. Haemostasis 1991, 21:27–31.

    PubMed  CAS  Google Scholar 

  34. Eichler P, Heinz-Juergen F, Lubenow N, et al.: Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 2000, 96:2373–2378.

    PubMed  CAS  Google Scholar 

  35. Maraganore JM, Adelman BA: Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes. Coronary Artery Disease 1996, 7:438–448.

    Article  PubMed  CAS  Google Scholar 

  36. Lewis BE, Wallis DE, Berkowitz SD, et al.: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001, 103:1838–1843. Prospective, historically controlled study of argatroban in patients with HIT or HITTS. Largest single study reported to date on argatroban for a group of investigators that have reported several smaller cases series.

    PubMed  CAS  Google Scholar 

  37. Matthai WH, Jr.: Use of argatroban during percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. Semin Thromb Hemost 1999, 25(suppl 1):57–60.

    PubMed  CAS  Google Scholar 

  38. Lewis BE, Matthai W, Grassman ED, et al.: Results of Phase 2/3 trial of argatroban anticoagulation during PTCA of patients with heparin-induced thrombocytopenia (HIT). Circulation 1997, 96:I217.

    Google Scholar 

  39. Greinacher A, Volpel H, Janssens U, et al.: Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999, 99:73–80. One of two studies in HIT patients treated with lepirudin with comparison of outcomes to historic controls.

    PubMed  CAS  Google Scholar 

  40. Greinacher A, Janssens U, Berg G, et al.: Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia: Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation 1999, 100:587–593. Second report from the same investigative group as Greinacher et al. [39 ] on lepirudin in patients with HIT.

    PubMed  CAS  Google Scholar 

  41. Campbell KR, Mahaffey KW, Lewis BE, et al.: Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invas Cardiol 2000, 12(suppl F):14F-19F. Review of overall experience of bivalirudin in patients undergoing PCI. The journal supplement containing this article is an excellent series of articles on bivalirudin.

    Google Scholar 

  42. Anand S, Yusuf S, Pogue J, et al.: Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction. Circulation 1998, 98:1064–1070.

    PubMed  CAS  Google Scholar 

  43. The OASIS-2 Investigators: Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 1999, 353:429–438.

    Article  Google Scholar 

  44. Antman EM: Hirudin in acute myocardial infarction — thrombolysis and thrombin in myocardial infarction (TIMI) 9B trial. Circulation 1996, 94:911–921.

    PubMed  CAS  Google Scholar 

  45. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators: a comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996, 335:775–782.

    Article  Google Scholar 

  46. Serruys PW, Herrman JPR, Simon R, et al.: A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995, 333:757–763.

    Article  PubMed  CAS  Google Scholar 

  47. Topol EJ, Bonan R, Jewitt D, et al.: Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993, 87:1622–1629.

    PubMed  CAS  Google Scholar 

  48. Bittl JA, Strony J, Brinker JA, et al.: Treatment with bivalirudin (HIRULOG) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995, 333:764–769.

    Article  PubMed  CAS  Google Scholar 

  49. Bittl JA, Chaitman BR, Feit F: Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: final reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001 (in press).

  50. Turpie AGG, Gallus AS, Hoek JA for the Pentasaccharide Investigators: A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001, 344:619–625.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Duke Clinical Research Institute, PO Box 17969, 27715, Durham, NC, USA

    Kenneth W. Mahaffey MD

Authors
  1. Kenneth W. Mahaffey MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mahaffey, K.W. Anticoagulation for acute coronary syndromes and percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Curr Cardiol Rep 3, 362–370 (2001). https://doi.org/10.1007/s11886-001-0052-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-001-0052-7

Keywords

Search

Navigation